BIRC3 mutations are another recurrent event in CLL with a relatively low frequency at diagnosis (3-4%) (18, 34, 55), but with a higher frequency in fludarabine-refractory patients (up to 24%) (55). This evidence concerns the gene BIRC3 and B-cell chronic lymphocytic leukemia.